(Reuters) – Bluebird bio’s treatment for a rare blood disorder received backing from advisers to the U.S. Food and Drug Administration on Friday, in a vote of confidence in gene therapies and bolstering the company beset by regulatory setbacks.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Maju Samuel)
